A citation-based method for searching scientific literature

Felicia Cosman, Daria B Crittenden, Serge Ferrari, E Michael Lewiecki, Juan Jaller-Raad, Cristiano Zerbini, Cassandra E Milmont, Paul D Meisner, Cesar Libanati, Andreas Grauer. J Bone Miner Res 2018
Times Cited: 35







List of co-cited articles
396 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Kenneth G Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C Karaplis, Mattias Lorentzon, Thierry Thomas, Judy Maddox, Michelle Fan, Paul D Meisner, Andreas Grauer. N Engl J Med 2017
468
80

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Felicia Cosman, Daria B Crittenden, Jonathan D Adachi, Neil Binkley, Edward Czerwinski, Serge Ferrari, Lorenz C Hofbauer, Edith Lau, E Michael Lewiecki, Akimitsu Miyauchi,[...]. N Engl J Med 2016
630
71

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Bente L Langdahl, Cesar Libanati, Daria B Crittenden, Michael A Bolognese, Jacques P Brown, Nadia S Daizadeh, Eva Dokoupilova, Klaus Engelke, Joel S Finkelstein, Harry K Genant,[...]. Lancet 2017
171
60

Romosozumab in postmenopausal women with low bone mineral density.
Michael R McClung, Andreas Grauer, Steven Boonen, Michael A Bolognese, Jacques P Brown, Adolfo Diez-Perez, Bente L Langdahl, Jean-Yves Reginster, Jose R Zanchetta, Scott M Wasserman,[...]. N Engl J Med 2014
677
60

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
E Michael Lewiecki, Rajani V Dinavahi, Marise Lazaretti-Castro, Peter R Ebeling, Jonathan D Adachi, Akimitsu Miyauchi, Evelien Gielen, Cassandra E Milmont, Cesar Libanati, Andreas Grauer. J Bone Miner Res 2019
64
45

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
R M Neer, C D Arnaud, J R Zanchetta, R Prince, G A Gaich, J Y Reginster, A B Hodsman, E F Eriksen, S Ish-Shalom, H K Genant,[...]. N Engl J Med 2001
42

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.
Desmond Padhi, Graham Jang, Brian Stouch, Liang Fang, Edward Posvar. J Bone Miner Res 2011
528
42

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Paul D Miller, Gary Hattersley, Bente Juel Riis, Gregory C Williams, Edith Lau, Luis Augusto Russo, Peter Alexandersen, Cristiano A F Zerbini, Ming-yi Hu, Alan G Harris,[...]. JAMA 2016
364
40

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
David L Kendler, Fernando Marin, Cristiano A F Zerbini, Luis A Russo, Susan L Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Péter Lakatos, Astrid Fahrleitner-Pammer,[...]. Lancet 2018
197
40

A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
E Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere, Kurt Lippuner, Paul D Meisner, Paul D Miller, Akimitsu Miyauchi, Judy Maddox, Li Chen, Stephane Horlait. J Clin Endocrinol Metab 2018
93
40

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
Michael R McClung, Jacques P Brown, Adolfo Diez-Perez, Heinrich Resch, John Caminis, Paul Meisner, Michael A Bolognese, Stefan Goemaere, Henry G Bone, Jose R Zanchetta,[...]. J Bone Miner Res 2018
85
40

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Paul M Wallace, Hang Lee, Robert M Neer, Sherri-Ann M Burnett-Bowie. Lancet 2015
236
37

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
Felicia Cosman, Daria B Crittenden, Serge Ferrari, Aliya Khan, Nancy E Lane, Kurt Lippuner, Toshio Matsumoto, Cassandra E Milmont, Cesar Libanati, Andreas Grauer. J Bone Miner Res 2018
51
34

Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.
Felicia Cosman, Jeri W Nieves, David W Dempster. J Bone Miner Res 2017
105
34

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Steven R Cummings, Javier San Martin, Michael R McClung, Ethel S Siris, Richard Eastell, Ian R Reid, Pierre Delmas, Holly B Zoog, Matt Austin, Andrea Wang,[...]. N Engl J Med 2009
28

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass.
Tony M Keaveny, Daria B Crittenden, Michael A Bolognese, Harry K Genant, Klaus Engelke, Beatriz Oliveri, Jacques P Brown, Bente L Langdahl, Chris Yan, Andreas Grauer,[...]. J Bone Miner Res 2017
45
25

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Ivo Valter, Lorraine A Fitzpatrick, Bente Juel Riis, Claus Christiansen, John P Bilezikian,[...]. Mayo Clin Proc 2017
70
25

Romosozumab for the treatment of osteoporosis.
Michael R McClung. Osteoporos Sarcopenia 2018
38
25

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.
Gary Hattersley, Thomas Dean, Braden A Corbin, Hila Bahar, Thomas J Gardella. Endocrinology 2016
137
22

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Henry G Bone, Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Lorraine A Fitzpatrick, Bruce Mitlak, Socrates Papapoulos, René Rizzoli,[...]. J Clin Endocrinol Metab 2018
73
22

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
Piet Geusens, Fernando Marin, David L Kendler, Luis A Russo, Cristiano Af Zerbini, Salvatore Minisola, Jean Jacques Body, Eric Lespessailles, Susan L Greenspan, Alicia Bagur,[...]. J Bone Miner Res 2018
49
22

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Dennis M Black, Pierre D Delmas, Richard Eastell, Ian R Reid, Steven Boonen, Jane A Cauley, Felicia Cosman, Péter Lakatos, Ping Chung Leung, Zulema Man,[...]. N Engl J Med 2007
22

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Richard Eastell, Clifford J Rosen, Dennis M Black, Angela M Cheung, M Hassan Murad, Dolores Shoback. J Clin Endocrinol Metab 2019
215
22

Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures.
J A Kanis, N C Harvey, E McCloskey, O Bruyère, N Veronese, M Lorentzon, C Cooper, R Rizzoli, G Adib, N Al-Daghri,[...]. Osteoporos Int 2020
86
22

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
D L Kendler, H G Bone, F Massari, E Gielen, S Palacios, J Maddox, C Yan, S Yue, R V Dinavahi, C Libanati,[...]. Osteoporos Int 2019
36
22

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.
M E Brunkow, J C Gardner, J Van Ness, B W Paeper, B R Kovacevich, S Proll, J E Skonier, L Zhao, P J Sabo, Y Fu,[...]. Am J Hum Genet 2001
675
22

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Henry G Bone, Rachel B Wagman, Maria L Brandi, Jacques P Brown, Roland Chapurlat, Steven R Cummings, Edward Czerwiński, Astrid Fahrleitner-Pammer, David L Kendler, Kurt Lippuner,[...]. Lancet Diabetes Endocrinol 2017
337
20

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Dennis M Black, Ann V Schwartz, Kristine E Ensrud, Jane A Cauley, Silvina Levis, Sara A Quandt, Suzanne Satterfield, Robert B Wallace, Douglas C Bauer, Lisa Palermo,[...]. JAMA 2006
904
20

Risk of subsequent fracture after prior fracture among older women.
A Balasubramanian, J Zhang, L Chen, D Wenkert, S G Daigle, A Grauer, J R Curtis. Osteoporos Int 2019
97
20

Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
Pascale Chavassieux, Roland Chapurlat, Nathalie Portero-Muzy, Jean-Paul Roux, Pedro Garcia, Jacques P Brown, Cesar Libanati, Rogely W Boyce, Andrea Wang, Andreas Grauer. J Bone Miner Res 2019
44
20

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study.
Piet Geusens, Mary Oates, Akimitsu Miyauchi, Jonathan D Adachi, Marise Lazaretti-Castro, Peter R Ebeling, Carlos Augusto Perez Niño, Cassandra E Milmont, Andreas Grauer, Cesar Libanati. JBMR Plus 2019
13
53

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.
John L Vahle, Masahiko Sato, Gerald G Long, Jamie K Young, Paul C Francis, Jeffery A Engelhardt, Michael S Westmore, Yanfei Linda, James B Nold. Toxicol Pathol 2002
433
17

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Paul D Miller, Pierre D Delmas, Robert Lindsay, Nelson B Watts, Marjorie Luckey, Jonathan Adachi, Kenneth Saag, Susan L Greenspan, Ego Seeman, Steven Boonen,[...]. J Clin Endocrinol Metab 2008
142
17

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
Steven Boonen, Fernando Marin, Barbara Obermayer-Pietsch, Maria E Simões, Clare Barker, Emmett V Glass, Peyman Hadji, George Lyritis, Heide Oertel, Thomas Nickelsen,[...]. J Clin Endocrinol Metab 2008
158
17

The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Elizabeth B Andrews, Alicia W Gilsenan, Kirk Midkiff, Beth Sherrill, Yun Wu, Beth H Mann, Daniel Masica. J Bone Miner Res 2012
168
17

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
P Hadji, J R Zanchetta, L Russo, C P Recknor, K G Saag, F E McKiernan, S L Silverman, J Alam, R T Burge, J H Krege,[...]. Osteoporos Int 2012
70
17

Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Benjamin Z Leder, Joy N Tsai, Alexander V Uihlein, Sherri-Ann M Burnett-Bowie, Yuli Zhu, Katelyn Foley, Hang Lee, Robert M Neer. J Clin Endocrinol Metab 2014
154
17

Imminent fracture risk.
C Roux, K Briot. Osteoporos Int 2017
90
17

Imminent risk of fracture after fracture.
H Johansson, K Siggeirsdóttir, N C Harvey, A Odén, V Gudnason, E McCloskey, G Sigurdsson, J A Kanis. Osteoporos Int 2017
144
17

Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Ian R Reid, Anne M Horne, Borislav Mihov, Angela Stewart, Elizabeth Garratt, Sumwai Wong, Katy R Wiessing, Mark J Bolland, Sonja Bastin, Gregory D Gamble. N Engl J Med 2018
149
17

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).
W Balemans, M Ebeling, N Patel, E Van Hul, P Olson, M Dioszegi, C Lacza, W Wuyts, J Van Den Ende, P Willems,[...]. Hum Mol Genet 2001
784
17

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Hideaki Ishibashi, Daria B Crittenden, Akimitsu Miyauchi, Cesar Libanati, Judy Maddox, Michelle Fan, Li Chen, Andreas Grauer. Bone 2017
40
17

Characteristics of recurrent fractures.
J A Kanis, H Johansson, A Odén, N C Harvey, V Gudnason, K M Sanders, G Sigurdsson, K Siggeirsdottir, L A Fitzpatrick, F Borgström,[...]. Osteoporos Int 2018
60
17

Risk of new vertebral fracture in the year following a fracture.
R Lindsay, S L Silverman, C Cooper, D A Hanley, I Barton, S B Broy, A Licata, L Benhamou, P Geusens, K Flowers,[...]. JAMA 2001
17

Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis.
Adolfo Díez-Pérez, Fernando Marin, Erik F Eriksen, David L Kendler, John H Krege, Miguel Delgado-Rodríguez. Bone 2019
39
17


Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Patricia Barrionuevo, Ekta Kapoor, Noor Asi, Fares Alahdab, Khaled Mohammed, Khalid Benkhadra, Jehad Almasri, Wigdan Farah, Maria Sarigianni, Kalpana Muthusamy,[...]. J Clin Endocrinol Metab 2019
84
17

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.
Dolores Shoback, Clifford J Rosen, Dennis M Black, Angela M Cheung, M Hassan Murad, Richard Eastell. J Clin Endocrinol Metab 2020
73
17

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Kenneth G Saag, Elizabeth Shane, Steven Boonen, Fernando Marín, David W Donley, Kathleen A Taylor, Gail P Dalsky, Robert Marcus. N Engl J Med 2007
533
14

The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.
Eugene V McCloskey, Helena Johansson, Anders Oden, Nicholas C Harvey, Hai Jiang, Sara Modin, Lorraine Fitzpatrick, John A Kanis. J Bone Miner Res 2017
29
17


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.